

Telescope Innovations Presents Continued Growth in Fiscal Year 2024

Increased revenues fueled major research and commercialization projects for intelligent automation products and advanced chemical manufacturing

Vancouver, British Columbia--(Newsfile Corp. - December 23, 2024) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) ("**Telescope**" or the "**Company**"), a developer of advanced technologies and services for the global pharmaceutical and chemical industries, reports financial results for the fiscal year ended August 31, 2024. The Company generated revenues of \$4.4 million during this period, with an Adjusted EBITDA loss of \$152 K (Figure 1). Revenues have been strategically reinvested to drive team growth and enhanced capacity for both R&D and commercialization activities. As a result, the Company achieved key milestones, including the launch of a multi-year, funded [collaboration with Pfizer to develop self-driving labs](#) and a global distribution agreement with Mettler Toledo for [DirectInject-LC™](#). During this period, Telescope Innovations also secured funding to construct a [pilot plant for lithium refinement](#) while advancing new IP in [lithium sulfide production](#) and [battery recycling](#).




Figure 1. Revenue and EBITDA for FY 23 and 24 in CAD, along with major milestones achieved in each

fiscal year.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/8923/234965_asset_25.jpg

FINANCIAL HIGHLIGHTS OF THE FISCAL YEAR ENDED AUGUST 31, 2024

All values are represented in CAD.

- Revenues of \$4.4 M, versus \$2.8 M for FY 2023, representing 57% revenue growth
- Expenses of \$5.8 M, versus \$3.5 M for FY 2023
- Adjusted EBITDA loss of \$152 K, versus loss of \$225 K for FY 2023

"Our progress this year reflects the strategic focus and innovation driving Telescope forward," commented Henry Dubina, Telescope CEO. "By reinvesting in groundbreaking projects like our collaboration with Pfizer on self-driving labs, the global rollout of DirectInject-LC™ with Mettler Toledo, and our advancements in lithium refinement and recycling technologies, we are building a solid foundation for sustainable growth and long-term industry leadership."

Readers are encouraged to review the full financial statements and accompanying management discussion and analysis for the fiscal year ended August 31, 2024, both of which are available under the profile for the Company on SEDAR+ (www.sedarplus.ca).

About Telescope

Telescope is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.

On behalf of the Board,

Telescope Innovations Corp.

Henry Dubina, Chief Executive Officer
E: hdubina@telescopeinn.com

The CSE has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit
<https://www.newsfilecorp.com/release/234965>